- A patient presents an oxycodone prescription from an out-of-state telemedicine provider the patient has never seen in person. Which of the following best analyzes the pharmacist's corresponding responsibility obligations?
Answer: The pharmacist must verify a valid prescriber-patient relationship and compliance with current telemedicine prescribing laws.
The pharmacist's corresponding responsibility requires evaluating whether an out-of-state telemedicine controlled substance prescription was issued pursuant to a legitimate prescriber-patient relationship and for a legitimate medical purpose. The Ryan Haight Online Pharmacy Consumer Protection Act established a general in-person evaluation requirement for online controlled substance prescribing; however, DEA and HHS have extended telemedicine prescribing flexibilities through December 31, 2026, which modify that requirement for certain qualifying telemedicine encounters. The pharmacist must evaluate compliance with whichever requirements are in force at the time of practice. A is incorrect because legal recognition of telemedicine does not automatically satisfy corresponding responsibility. B is incorrect because facial validity does not satisfy corresponding responsibility when legitimacy of the prescriber-patient relationship remains unresolved. D is incorrect because documentation of a visit is not the statutory standard; the underlying question is whether the applicable prescribing requirements were met.
- A pharmacist notices a red flag -- an unusually high quantity -- on a controlled substance prescription. She calls the prescriber's office, is told the prescriber is unavailable, and leaves a message. Two hours later with no callback, she fills the prescription. Which of the following best analyzes this decision?
Answer: The pharmacist failed to resolve the red flag; corresponding responsibility requires confirmation of legitimacy before dispensing, not just an unanswered message.
Corresponding responsibility requires actual resolution of red flags, not merely an attempt to resolve them. An unanswered message does not resolve the concern. The pharmacist should make additional attempts to contact the prescriber or decline to fill until the concern is addressed. A is incorrect because corresponding responsibility cannot be shifted back to the prescriber simply by attempting a call. B is incorrect because patient wait time does not override the obligation to resolve red flags before filling a suspicious prescription. C is incorrect because leaving a message and receiving no answer does not constitute verification.
- A patient presents a prescription for oxycodone, alprazolam, and carisoprodol all written by the same physician on the same day -- a combination sometimes called the holy trinity. Which of the following best describes the pharmacist's obligation?
Answer: The pharmacist should verify the prescription's legitimacy by consulting the PDMP and contacting the prescriber before deciding to fill or refuse the medications.
The holy trinity combination is a well-documented red flag in DEA guidance and controlled substance abuse literature. A pharmacist presented with this pattern must exercise corresponding responsibility by investigating through PDMP review and prescriber contact, and must decline to fill if a legitimate clinical basis cannot be confirmed. A is incorrect because physician licensure does not guarantee the prescription was issued for legitimate purposes. B is incorrect because face validity does not satisfy corresponding responsibility when red flags exist. D is incorrect because the concern is the aggregate combination; the pattern as a whole is the red flag.
- A patient consistently pays cash for expensive Schedule II opioid prescriptions at a pharmacy where most patients use insurance. Which of the following best describes whether this factor is relevant to the pharmacist's corresponding responsibility analysis?
Answer: Cash payment is a red flag suggesting potential illegitimacy, warranting further investigation alongside other factors in the pharmacist's responsibility analysis.
Cash payment for controlled substances is a recognized red flag because it avoids insurance record trails. It is one factor in the overall corresponding responsibility analysis -- not sufficient alone to require refusal, but significant when combined with other indicators. A is incorrect because the method of payment is a relevant red flag factor. B is incorrect because cash payment alone is not sufficient to establish that a prescription lacks legitimate medical purpose. D is incorrect because it is the behavior, not the insurance status, that raises the flag.
- A pharmacist has growing concerns about a prescriber whose patients frequently request the same opioid combination, all pay cash, and several show no visible signs of the chronic pain conditions listed on their prescriptions. No individual prescription is certain to be invalid. Which of the following best applies?
Answer: The pharmacist may decline to fill prescriptions due to a pattern of red flags.
Corresponding responsibility extends to patterns of prescribing, not only individual prescriptions. A consistent pattern of red flags across multiple patients from the same prescriber raises serious legitimacy concerns. The pharmacist may decline to fill and should document the basis for the decision. A is incorrect because face validity of individual prescriptions does not override a pattern raising corresponding responsibility concerns. B is incorrect because the pharmacist does not need DEA confirmation; professional judgment based on observable patterns is sufficient. C is incorrect because filling while secretly marking patients does not satisfy corresponding responsibility.
- What is the key distinction between a prescription that is technically valid on its face and one that satisfies the pharmacist's corresponding responsibility?
Answer: A prescription must be issued for a legitimate medical purpose to satisfy corresponding responsibility.
The central concept of corresponding responsibility is that face validity is insufficient. A prescription may have all required elements and yet be a purported prescription issued outside the usual course of professional practice. The pharmacist must exercise judgment about the legitimacy of the prescription's purpose, not only check boxes for required elements. A is incorrect because this is the most common failure mode in corresponding responsibility analysis. C is incorrect because a valid DEA number is one element of face validity but does not establish that the prescription was issued for a legitimate medical purpose. D is incorrect because DUR checks assess clinical appropriateness but do not evaluate whether the prescription was issued for legitimate purposes.
- A pharmacist declines to fill a Schedule II prescription because she believes it was not issued for a legitimate medical purpose. The patient demands an explanation. Which of the following best describes the pharmacist's obligations regarding documentation and communication?
Answer: The pharmacist should document the refusal in her records, inform the patient professionally, and advise consulting the prescriber without sharing specific suspicions.
When declining based on corresponding responsibility concerns, the pharmacist should document the specific concerns in her records, inform the patient professionally, advise consultation with the prescriber, and return the prescription. Confiscation is not appropriate, and specific investigative suspicions should not be disclosed to the patient. A is incorrect because documentation of the basis for refusal is important for professional and legal protection. B is incorrect because DEA reporting may be appropriate in some situations but is not the first step before communicating with the patient. C is incorrect because a formal written explanation to the patient is not legally required for a corresponding responsibility-based refusal.
- A pharmacist notices through the state PDMP that a patient has received oxycodone prescriptions from three different physicians in the same 30-day period. The patient now presents a new oxycodone prescription from a fourth physician. Which of the following best describes the pharmacist's obligation?
Answer: The pharmacist must verify the prescription's legitimacy by contacting the prescriber and reviewing the PDMP before dispensing.
Multiple prescribers for the same controlled substance within the same period is a significant red flag for doctor shopping. The pharmacist is obligated to investigate before filling. B is incorrect because face validity does not overcome the red flag raised by the prescribing pattern. C is incorrect because investigation and resolution come before reporting. D is incorrect because PDMP data is specifically provided to pharmacists to inform dispensing decisions and may be used to identify patterns triggering corresponding responsibility obligations.
- A state law requires pharmacists to check the PDMP before filling Schedule II prescriptions. A patient presents a Schedule II opioid prescription but the PDMP system is down for maintenance. Which of the following best applies?
Answer: The pharmacist must wait to fill until the PDMP is available unless state law allows exceptions for system outages.
When state law mandates PDMP checks before dispensing and the system is unavailable, the pharmacist generally cannot fill without the required check unless the state law includes a system outage exception. Many states have such provisions allowing filling with documentation of the outage. A is incorrect because unavailability of the PDMP does not automatically authorize filling when the check is legally required. C is incorrect because many states have outage exception provisions, and in some states the check can be completed once the system is available. D is incorrect because the patient counseling record is not the appropriate documentation mechanism.
- A patient calls requesting an early refill of a Schedule II opioid, stating she dropped them in the toilet. She last filled 10 days ago for a 30-day supply. Which of the following best applies?
Answer: Schedule II controlled substances cannot be refilled; the patient must obtain a new prescription from her prescriber.
Schedule II prescriptions cannot be refilled; a new prescription is required for each dispensing. A lost controlled substance claim, particularly when early in the supply period, is a recognized red flag for potential diversion. The pharmacist should advise the patient to contact the prescriber for a new prescription. B is incorrect because inability to disprove a claim does not obligate filling when red flags are present. C is incorrect because while Schedule II partial fills are permitted under current federal law -- including at a patient's or prescriber's request with the remainder filled within 30 days -- a partial fill in response to a lost-medication claim does not resolve the underlying red flag and is not the appropriate response here. D is incorrect because compassionate concern does not override corresponding responsibility and the Schedule II no-refill rule.
- A patient presenting an oxycodone prescription demands it be filled immediately, refuses to wait for a PDMP check, and insists on immediate-release rather than extended-release formulation. Which of the following best applies?
Answer: The pharmacist may refuse to fill due to red flags indicating potential prescription misuse.
Patient behavior signaling drug-seeking -- demanding immediate dispensing without allowing verification, resisting PDMP checks, and insisting on higher-abuse-potential formulations -- is a recognized red flag under corresponding responsibility. The pharmacist may decline based on these behavioral indicators. A is incorrect because PDMP checks and verification steps are part of the pharmacist's corresponding responsibility obligation; refusing to allow them is itself a red flag. B is incorrect because insistence on a specific formulation associated with faster onset is a clinical concern, not merely a preference. D is incorrect because proceeding to fill while flagging does not satisfy current corresponding responsibility obligations.
- A patient presents an oxycodone prescription for chronic back pain written by a dermatologist. Which of the following best applies to the pharmacist's corresponding responsibility analysis?
Answer: The pharmacist should verify the prescription's legitimacy and appropriateness with the dermatologist before filling.
A prescription for chronic pain opioids from a dermatologist is a potential red flag because pain management falls outside the typical scope of dermatology practice. While physicians may sometimes practice outside their primary specialty, this pattern warrants verification with the prescriber before filling. A is incorrect because having DEA authority does not ensure the prescriber is acting within their usual course of professional practice for this specific prescription. C is incorrect as an absolute rule; refusal without investigation is premature. D is incorrect because prescriber specialty, while not a required prescription element, is relevant to corresponding responsibility analysis.
- A pharmacist has filled controlled substance prescriptions for a patient for two years without concerns. Recently, the prescriptions show increasing doses at shorter intervals, more frequent early refill requests, and the most recent prescription is from a different prescriber. How should the pharmacist analyze the current prescription?
Answer: The pharmacist must assess the prescription for red flags, including dose escalation, early refills, and prescriber change, before filling.
Corresponding responsibility requires ongoing evaluation of each prescription, not a one-time assessment. Even a patient with a previously legitimate prescription history may develop red flag patterns over time. The pharmacist must evaluate the current prescription in light of the entire pattern: dose escalation, early refill requests, and prescriber change are all red flags that must be addressed. B is incorrect because established prescription history does not immunize current prescriptions from corresponding responsibility analysis. C is incorrect because while changing prescribers is a right, doing so in a pattern associated with doctor shopping is a red flag. D is incorrect because DEA reporting may be appropriate but is not the first step.
- A pharmacist fills a controlled substance prescription without red flag concerns. A DEA investigation later reveals the prescription was forged, but the forgery was sophisticated and undetectable by ordinary professional attention. Which of the following best describes the pharmacist's corresponding responsibility liability?
Answer: The pharmacist is not liable if they exercised appropriate professional attention without knowledge of the forgery.
Corresponding responsibility is not a strict liability standard. The pharmacist is liable for filling a prescription they knew or reasonably should have known was not legitimate. A sophisticated forgery undetectable with ordinary professional attention does not create corresponding responsibility liability because the pharmacist lacked actual or constructive knowledge. A is incorrect because strict liability is not the standard. B is incorrect because it overstates the exemption; if the pharmacist should have detected warning signs and did not, they may be liable. D is incorrect because the patient's subsequent criminal activity does not retroactively determine the pharmacist's corresponding responsibility.
- A pharmacist is presented on the same day with 20 patients from the same prescriber, all with the same combination of controlled substances, all paying cash, and all from the same zip code. The pharmacist has never filled prescriptions from this prescriber before. Which of the following best analyzes the situation?
Answer: The pharmacist should decline to fill due to red flags indicating prescriptions may not be issued in usual professional practice.
The scenario presents a cluster of classic red flags: same unknown prescriber, identical prescription combinations, cash payment, same geographic origin, and 20 patients on a single day. The pharmacist's core corresponding responsibility obligation under 21 CFR 1306.04 is to decline to fill prescriptions that cannot be verified as issued for a legitimate medical purpose in the usual course of professional practice. Reporting to the DEA or state board may be a prudent and appropriate step given a pattern this strong, but the corresponding responsibility doctrine itself imposes a duty to refuse -- not a universal reporting mandate. A is incorrect because patient access concerns do not override corresponding responsibility when red flags are this numerous and systematic. C is incorrect because selective filling without a principled resolution of the red flags is not appropriate. D is incorrect because a single prescriber contact for 20 patients presenting this aggregate pattern is inadequate to resolve the red flags.
- A pharmacist receives a Schedule II prescription that appears potentially forged -- the prescription paper looks different from others from this office and the handwriting appears inconsistent; additionally, no frequency is specified. Which of the following best applies?
Answer: The pharmacist must verify prescription legitimacy before filling due to suspicious characteristics and missing frequency.
Multiple red flags are present: suspicious physical characteristics and a missing required prescription element. The pharmacist should not fill until legitimacy is verified by contacting the prescriber using an independently verified phone number, not a number that could have been added by a forger. B is incorrect because corresponding responsibility does not require certainty of forgery before declining; red flags justify withholding pending verification. C is incorrect because filling any portion before verification is not appropriate. D is incorrect because filling while flagging does not satisfy the pharmacist's corresponding responsibility obligation.
- A patient presents an oxycodone prescription that appears authentic and valid. A PDMP review shows the same patient has filled the same prescription at three other pharmacies during the same week, all from the same physician. The prescribing physician's awareness of the multiple fills is unknown. Which of the following best analyzes the situation?
Answer: The pharmacist should verify with the prescriber if multiple fills are authorized and decline to fill if the prescriber is unaware or lacks a legitimate explanation.
Multiple fills of the same prescription at different pharmacies within the same week is a classic indicator of prescription fraud or diversion. The pharmacist must contact the prescriber to determine whether the multiple fills are clinically authorized. If unauthorized or unexplained, the pharmacist must decline. A is incorrect because multiple same-week fills from the same physician are suspicious even if from one prescriber; the prescriber may be unaware. B is incorrect because corresponding responsibility requires the pharmacist to consider the full picture visible in PDMP data, not only what happens at her own pharmacy. D is incorrect because investigating comes before reporting and before any dispensing decision.
- A pharmacist calls a prescriber to verify an unusually high-dose Schedule II opioid prescription. The prescriber confirms the prescription is legitimate and provides a satisfactory clinical rationale. Which of the following best describes the pharmacist's situation after this conversation?
Answer: The pharmacist may fill the prescription after documenting the prescriber's satisfactory clinical rationale and conversation details.
Resolving red flags through good-faith prescriber contact that yields a satisfactory clinical explanation appropriately satisfies the pharmacist's corresponding responsibility obligation and allows the prescription to be filled, with documentation of the verification. A is incorrect because while prescriber confirmation generally resolves the concern, the pharmacist's judgment about adequacy of the explanation remains; an unsatisfactory explanation still allows declining. B is incorrect because resolving red flags through prescriber verification is exactly what corresponding responsibility contemplates. C is partially correct about documentation but understates that after satisfactory verification, the prescription may be filled.
- A physician who is a DEA registrant calls the pharmacy asking to fill a prescription for oxycodone 80 mg for himself, stating he has chronic back pain and has been self-prescribing for several years. Which of the following best analyzes the pharmacist's corresponding responsibility?
Answer: The pharmacist should decline to fill the prescription as self-prescribing controlled substances is not in the usual course of professional practice.
Self-prescribing of controlled substances is one of the clearest corresponding responsibility red flags. Under 21 CFR 1306.04, a valid controlled substance prescription must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice; a physician treating his own chronic pain condition with Schedule II opioids does not clearly satisfy this standard. Additionally, many state laws restrict or prohibit self-prescribing of controlled substances, though the specific rules vary by jurisdiction. The pharmacist should decline to fill the prescription. A is incorrect because DEA registration authorizes prescribing for patients, not for oneself; registration status alone does not resolve the corresponding responsibility analysis. C is incorrect because a physician's self-assessment of his own medical needs does not satisfy the corresponding responsibility standard, which requires the pharmacist to make an independent evaluation of prescription legitimacy. D is incorrect because there is no first-occurrence exception to the self-prescribing red flag analysis.
- Under 21 CFR 1306.04(a), which of the following best describes the concept of corresponding responsibility as it applies to pharmacists dispensing controlled substances?
Answer: Corresponding responsibility means the pharmacist shares legal responsibility with the prescriber to ensure prescriptions are for legitimate medical purposes.
21 CFR 1306.04(a) establishes shared responsibility: the prescriber bears primary responsibility for appropriate prescribing, but the pharmacist has a corresponding (shared) responsibility. A pharmacist who knowingly fills a prescription not issued for a legitimate medical purpose is subject to the same legal penalties as the prescriber. A is incorrect because corresponding responsibility does not relieve the prescriber; it adds the pharmacist's responsibility alongside the prescriber's. B is incorrect because DEA verification is one element but corresponding responsibility encompasses the entire legitimacy of the prescription's purpose and the prescriber's practice context. C is incorrect because PDMP checking is one tool for exercising corresponding responsibility, not the definition of it.
